Strongbridge Biopharma plc Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2019; Revises Revenue Guidance for the Year Ended December 31, 2019; Provides Revenue Guidance for the Full Year 2020
For the year ended December 31, 2019, the company expected net product sales of approximately $21.7 million, exceeding its previous $18 to $20 million guidance range.
For the year 2020, the company expected revenue guidance will be approximately $26 to $27 million.